Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/284/testing-a-vaccine-for-treating-or-preventing-triple-negative-breast-cancer
Clinicaltrials.gov identifier:
NCT04674306 (https://clinicaltrials.gov/show/NCT04674306)
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy
About the Study
NOTE: This study is no longer recruiting people.
Researchers are studying the affects of this breast cancer vaccine on the immune system in the following groups:
- Prevention arm:
- people with an inherited mutation in BRCA1, BRCA2, or PALB2, who have not been diagnosed with cancer, and who are planning to undergo a risk-reducing mastectomy.
- Treatment arms:
- people diagnosed with stage 2 or stage 3 triple-negative breast cancer who have completed treatment and are considered at high risk for recurrence.
- people diagnosed with stage 2 or stage 3 triple-negative breast cancer who have completed chemotherapy and radiation and are currently receiving Keytruda (pembrolizumab).
This Study is Open To:
NOTE: This study is no longer recruiting people.
This Study is Not Open To:
NOTE: This study is no longer recruiting people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.